Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

- PMLiVE

Novartis negotiates ex-US rights to Spark gene therapy

Strikes $170m deal for Luxturna

- PMLiVE

EMA hands UniQure orphan status first in Huntington’s

The Dutch biotech expects to file the treatment for approval later this year

The tipping point

Accelerating biosimilar uptake through medical education

- PMLiVE

Takeda bags EU approval for Adcetris in lymphoma

Data shows the drug improves PFS and symptom burden in CTCL patients

Novartis day

Novartis doubles down on biosimilars with Biocon alliance

The companies will develop multiple immunology and oncology biosimilars

- PMLiVE

Novartis gets speedy reviews for new Kymriah filings

US and EU regulatory agencies will review the drug for DLBCL patients

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

- PMLiVE

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

She succeeds Bruno Strigini who retires

- PMLiVE

Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

The head-to-head trials will evaluate findings in patients with PsA and AS

- PMLiVE

Takeda ties-up with Denali Therapeutics for neuroscience boost

The companies will develop new therapies for conditions such as Alzheimer’s

- PMLiVE

Takeda offers €520m for stem cell firm TiGenix

The deal will go ahead if the Japanese pharma company can secure an 85% stake in the biotech

- PMLiVE

Novartis’ Promacta receives US breakthrough therapy designation

Regulatory filings of the rare blood disorder treatment are expected this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links